PainChek (ASX:PCK) said its annual recurring revenue grew to AU$4 million at the end of January with the implementation of licenses, and it anticipates an annual recurring revenue of AU$5.6 million after all licenses have been implemented, according to a Friday Australian bourse filing.
The company also has a pipeline for about AU$1.9 million in annual recurring revenue under negotiation across US, Canada, UK, and Australia-New Zealand, the filing said.
The company plans to continue negotiating with the Centers for Medicare & Medicaid Services in the US for an additional specific PainChek Current Procedural Terminology reimbursement code by April, per the filing.